Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07216495

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Jasmine Sukumar, MD

CONTACT

[email protected]

713-264-1576

Jasmine Sukumar, MD

PRINCIPAL_INVESTIGATOR

About this study

Primary Objective To evaluate the feasibility of a supervised cardiorespiratory exercise program in patients with clinical stage 2-3 Triple Negative Breast Cancer (TNBC) undergoing neoadjuvant chemotherapy with immune checkpoint inhibitor therapy.

Secondary Objectives To explore the relationship between cardiorespiratory exercise and circulating immune (CD8+ T) cells in the peripheral blood.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • female and male participants 18 years or older and willing to provide Informed Consent
  • clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 (HER2) negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization))
  • Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device
  • Eastern Co-Operative Oncology Group (ECOG) Performance Status 0-1
  • Planned receipt of neoadjuvant chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel)
  • clearance to participate in the study by the patient's medical oncologist
  • normal bone marrow function
  • able to read/complete study forms/assessments and understand instructions in English

Exclusion criteria

a) Any physical condition which hinders the ability to safely participate in exercise including: uncontrolled or symptomatic cardiac/respiratory disease (e.g. uncontrolled angina, unusual shortness of breath, congestive heart failure, symptomatic peripheral vascular disease), stroke/myocardial infarction in the past year, fragility fracture, recent or planned orthopedic surgery, or any comorbid condition precluding exercise per the treating physician b) receipt of medications known to influence immune function including corticosteroids (>10 mg prednisone equivalent), other immune-suppressive medication, or beta blockers47 c) Any infection or vaccination within the last 4 weeks d) e) Known HIV-positive participants on combination antiretroviral therapy f) concurrent participation in a therapeutic clinical trial or other exercise program g) pregnant h) medically advised to not exercise i) Unable to walk on a motor-driven treadmill for ~30 minutes at study enrollment j) Adults unable to consent k) No external catheters/drains (e.g., nephrostomy tube, foley catheter). A colostomy or Ileostomy is acceptable.

l) Prior or concurrent non-breast malignancy. Those with prior cancers treated with curative intent are eligible. Participants with known (or history) of hepatitis B positive, or hepatitis C positive infection

Treatment and study plan

Exercise

Other

Cardiorespiratory training via treadmill walking for 30 minutes; participants will be supervised by a trained exercise physiologist.

Primary outcomes

  1. Adherence

    Time frame: Approximately 8 weeks

    Feasibility will be measured by adherence to both exercise frequency and time (duration/intensity) at the supervised sessions.

Secondary outcomes

  1. Circulating immune (CD8+ T) cells in the peripheral blood

    Time frame: Approximately 8 weeks

    Change of CD8+ T cells in the peripheral blood from baseline (pre-exercise) to post-exercise state

Other outcomes

  1. Other blood-based circulating immune cells pre-, during-, and post-exercise

    Time frame: Approximately 8 weeks

    NK cells, T regulatory (Treg) cells, markers of T cell exhaustion and immunosenescence (CD57, CD45-RA, PD1, KLRG1, CTLA-4)

  2. VO2 peak/max

    Time frame: Approximately 8 weeks

    peak oxygen uptake

  3. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (general cancer)

    Time frame: Approximately 8 weeks

    This is a Patient-Reported Outcome to measure health-related quality of life in patients with cancer. The instrument consists of 30 items comprising five functional scales (physical, role, emotional, cognitive, and social functioning), one global health status/quality of life scale, three multi-item symptom scales (fatigue, pain, nausea/vomiting), and several single-item symptom measures (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).Responses are scored and transfored to a 0-100 scale. Responses are scored and linearly transformed to a 0-100 scale. For functional scales and the global health status/quality of life scale, higher scores indicate better functioning or quality of life. For symptom scales and single-item measures, higher scores indicate greater symptom severity or burden.

  4. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BR42 (breast-specific module)

    Time frame: Approximately 8 weeks

    This is a Patient-Reported Outcome to measure of quality of life patients with breast cancer. The instrument includes multi-item and single-item scales assessing domains such as systemic therapy side effects, breast and arm symptoms, body image, sexual functioning, sexual enjoyment, future perspective, and treatment-related symptoms. Scores are linearly transformed to a 0-100 scale. For functional scales (e.g., body image, sexual functioning, future perspective), higher scores indicate better functioning. For symptom scales/items (e.g., breast symptoms, systemic therapy side effects), higher scores indicate greater symptom burden or severity.

  5. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-FA12

    Time frame: Approximately 8 weeks

    This is a Patient-Reported Outcome of multidimensional fatigue in patients with cancer. The instrument consists of 12 items evaluating physical fatigue, emotional fatigue, and cognitive fatigue, as well as the extent to which fatigue interferes with daily activities and social functioning. Responses are scored and linearly transformed to a 0-100 scale. Higher scores indicate greater fatigue severity and greater interference with functioning.

  6. Breast surgical outcome

    Time frame: Approximately 6 months

    Pathologic complete response (pCR) rate

  7. Safety of chemotherapy and ICI therapy

    Time frame: Approximately 8 weeks

    Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0)

  8. Activity Tracker Data from home walking program: heart rate

    Time frame: Approximately 6 months

    heart rate in beats per minute

  9. Activity Tracker Data from home walking program: step counts

    Time frame: Approximately 6 months

    steps per day

  10. Data from home walking program: active/sedentary time

    Time frame: Approximately 6 months

    number of active versus sedentary minutes per day

  11. Godin Leisure Time Physical Activity Questionnaire

    Time frame: Approximately 8 weeks

    This is a self-administered instrument used to quantify frequency of leisure time physical activity during a typical 7-day period. Participants report the number of times per week they engage in activities lasting ≥15 minutes at three intensity levels: strenuous (vigorous), moderate, and light (mild). A Leisure Score Index (LSI) will be calculated using the formula: (9 × number of strenuous sessions) + (5 × number of moderate sessions) + (3 × number of light sessions). Scores reflect weighted weekly leisure-time physical activity, with higher scores indicating greater self-reported activity levels. There is no absolute maximum score; a score of 0 indicates no reported leisure-time physical activity.

  12. Short Physical Performance Battery (SPPB)

    Time frame: Approximately 8 weeks

    Measure of functional mobility (balance, lower extremity strength, and functional capacity) through assessment of 3 components (balance test, gait speed test, and chair stand test). Each component is scored from 0-4 points, for a total score range of 0-12. Higher scores indicate better functional mobility.

Study contacts

Contact information is provided by the study sponsor or research team.

Livia Geoffrey

CONTACT

[email protected]

832-728-6175

Salma Foster

CONTACT

[email protected]

713-794-1613

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Official study title

Pilot Study of an Aerobic Exercise Intervention During Immune Checkpoint Inhibitor Therapy in Early-stage Triple Negative Breast Cancer

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Oct 14, 2025
Registry last updated
Apr 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.